Combination therapies with checkpoint inhibitors: What are the promising avenues? (Including discussion of 57O and 136O)

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session ESMO-IASLC Best Abstracts: The evolving landscape of immunotherapy
Topics Cytotoxic agents
Immunotherapy
Thoracic malignancies
Therapy
Biological therapy
Presenter Johan Vansteenkiste
Authors J.F. Vansteenkiste
  • Respiratory Oncology Unit (pulmonology)  , University Hospital KU Leuven, 3000 - Leuven/BE